代表性教學(xué)、科研項目或研究成果(論文、專利專著、教材、成果獲獎): | 1、科研項目: (1)北京市衛(wèi)生健康委員會高層次公共衛(wèi)生技術(shù)人才培養(yǎng)計劃,學(xué)科骨干,項目編號:2022-3-041,42萬,執(zhí)行年限2022.4-2025.4 (2)首都衛(wèi)生發(fā)展科研專項項目自主創(chuàng)新項目,基于多交叉恒溫擴增的兒童結(jié)核病分子診斷技術(shù)研發(fā)及臨床驗證,項目編號首發(fā)2020-2-1142,30萬,執(zhí)行年限2020.1-2022.12 (3)北京市優(yōu)秀人才培養(yǎng)資助青年拔尖個人項目,項目編號2016000021223ZK38,50萬,執(zhí)行年限2016.9-2019.9 (4)國家自然科學(xué)基金應(yīng)急管理項目,結(jié)核分枝桿菌rpoA/C突變在利福平耐藥及菌株傳播中的作用,項目編號81541062,12萬,執(zhí)行年限2016.1-2016.12 (5)北京市衛(wèi)生系統(tǒng)高層次衛(wèi)生技術(shù)人才培養(yǎng)計劃,學(xué)科骨干,項目編號2015-3-081,21萬,執(zhí)行年限2015.12-2018.12 (6)首都衛(wèi)生發(fā)展科研專項項目青年項目,兒童結(jié)核病病原體分子鑒定和耐藥分子特征研究,項目編號首發(fā)2011-1007-01,8萬,執(zhí)行年限2012.8-2015.8 (7)北京市留學(xué)人員科技活動擇優(yōu)資助項目,兒童結(jié)核病感染菌株鑒定及耐藥性研究,15萬,執(zhí)行年限2011-2012年 (8)國家自然科學(xué)基金青年項目,結(jié)核分枝桿菌embB基因突變的生物學(xué)效應(yīng)研究,項目編號30901632,21萬,執(zhí)行年限2010.1-2012.12 (9)北京市科技新星計劃(A類),依托面上項目:宿主基因多態(tài)性與結(jié)核分枝桿菌易感性的關(guān)系研究,項目編號2008A079,8萬,執(zhí)行年限2009.1-2011.12 2、代表性論文: (1) Zhdanova S*, Jiao WW*, Sinkov V, Khromova P, Solovieva N, Mushkin A, Mokrousov I, Belopolskaya O, Masharsky A, Vyazovaya A, Rychkova L, Kolesnikova L, Zhuravlev V, Shen AD, Ogarkov O. Insight into Population Structure and Drug Resistance of Pediatric Tuberculosis Strains from China and Russia Gained through Whole-Genome Sequencing. Int J Mol Sci, 2023, 24, 10302. (2) Jiang TT#, Sun L#, Wang TY, Qi H, Tang H, Wang YC, Han Q, Shi XQ, Bi J*, Jiao WW*, Shen AD*. The clinical significance of macrolide resistance in pediatric Mycoplasma pneumoniae infection during COVID-19 pandemic. Front Cell Infect Microbiol, 2023; 13: 1181402. (3) Liao Q#, Zheng Y#, Wang Y#, Ye L#, Liu X#, Jiao W#, Liu Y, Zhu Y, Jia J, Sun L*, Shen A*, Wan C*. Effectiveness of Bacillus Calmette-Guérin vaccination against severe childhood tuberculosis in China: a case-based, multicenter retrospective study. Int J Infect Dis. 2022, 121: 113-119. (4) Jiao WW#, Wang GR#, Sun L, Xiao J, Li JQ, Wang YC, Quan ST, Huang HR*, Shen AD*. Multiple Cross Displacement Amplification Combined With Real-Time Polymerase Chain Reaction Platform: A Rapid, Sensitive Method to Detect Mycobacterium tuberculosis. Front. Microbiol. 2021, 12: 812690. doi: 10.3389/fmicb.2021.812690. (5) Wang XY, Wang GR, Wang YC, Quan ST, Qi H, Sun L, Shen C, Huang HR, Jiao WW*, Shen AD*. Development and preliminary application of multiplex loop-mediated isothermal amplification coupled with lateral flow biosensor for detection of Mycobacterium tuberculosis complex. Front Cell Infect Microbiol. 2021, 11: 666492. (6) Jiao WW, Wang Y, Wang GR, Wang YC, Xiao J, Sun L, Li JQ, Wen SA, Zhang TT, Ma Q, Huang HR*, Shen AD*. Development and Clinical Validation of Multiple Cross Displacement Amplification Combined With Nanoparticles-Based Biosensor for Detection of Mycobacterium tuberculosis: Preliminary Results. Front. Microbiol. 2019, 10:2135. (7) Li QJ#, Jiao WW#, Yin QQ, Li YJ, Li JQ, Xu F, Sun L, Xiao J, Qi H, Wang T, Mokrousov I, Huang HR*, Shen AD*. Positive epistasis of major low-cost drug resistance mutations rpoB531-TTG and katG315-ACC depends on the phylogenetic background of Mycobacterium tuberculosis strains. Int J Antimicrob Agents. 2017, 49(6):757-762. (8) Li QJ#, Jiao WW#, Yin QQ, Xu F, Li JQ, Sun L, Xiao J, Li YJ, Mokrousov I, Huang HR*, Shen AD*. Compensatory Mutations of Rifampin Resistance Are Associated with Transmission of Multidrug-Resistant Mycobacterium tuberculosis Beijing Genotype Strains in China. Antimicrob Agents Chemother. 2016, 60(5): 2807-2812. 3、成果獲獎: (1)2021年度北京醫(yī)學(xué)科技獎二等獎,《結(jié)核病診斷新技術(shù)的建立及推廣應(yīng)用》,第九完成人。 (2)2021年度首都醫(yī)科大學(xué)自然科學(xué)技術(shù)獎三等獎,《呼吸道病原體分子診斷技術(shù)的研發(fā)及臨床評估》,第二完成人。 (3)2022年度中華醫(yī)學(xué)科學(xué)技術(shù)獎三等獎,《結(jié)核病關(guān)鍵診療技術(shù)的建立及推廣應(yīng)用》,第八完成人。 (4)2022年度北京市科技進步獎二等獎,《結(jié)核病關(guān)鍵診斷技術(shù)的創(chuàng)新性建立及應(yīng)用》,第三完成人。 |